沙库巴曲缬沙坦钠治疗射血分数降低的慢性心力衰竭患者的临床疗效研究  

Study on clinical efficacy of sacubitril valsartan sodium in the treatment of chronic heart failure with reduced ejection fraction

作　　者：任静娟 REN Jing-juan(Department of Cardiovascular Medicine,Hulunbuir People's Hospital,Hulunbuir 021000,China)

机构地区：[1]呼伦贝尔市人民医院心血管内科,021000

出　　处：《中国实用医药》2023年第17期84-87,共4页China Practical Medicine

摘　　要：目的 观察使用沙库巴曲缬沙坦钠治疗射血分数降低的慢性心力衰竭(HFrEF)患者的临床疗效。方法 80例射血分数降低的慢性心力衰竭患者,随机分为对照组和观察组,每组40例。对照组口服盐酸贝那普利,观察组连续停止口服血管紧张素转化酶抑制剂(ACEI)36 h后,开始口服沙库巴曲缬沙坦钠。比较两组患者治疗效果、不良反应发生情况以及心功能指标[6 min步行距离、明尼苏达州心功能不全生命质量量表(MLHFQ)评分、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、氨基末端脑利钠肽前体(NT-proBNP)]水平。结果 治疗后,观察组治疗总有效率90.0%高于对照组的67.5%,差异有统计学意义(P<0.05)。观察组患者6 min步行距离(346.74±49.66)m长于对照组的(269.60±52.81)m, MLHFQ评分(32.40±3.48)分、LVEDD(57.67±2.54)mm、NT-proBNP(2329.74±412.15)pg/ml低于对照组的(39.28±3.89)分、(61.24±3.31)mm、(3847.60±517.00)pg/ml, LVEF(48.67±2.20)%高于对照组的(41.20±2.81)%,差异均具有统计学意义(P<0.05)。观察组不良反应发生率12.5%与对照组的10.0%比较,差异无统计学意义(P>0.05)。结论 沙库巴曲缬沙坦钠治疗射血分数降低的慢性心力衰竭患者临床效果更优良,心力衰竭指标改善更明显,并有显著的安全性,可以进一步临床推广应用。Objective To observe the clinical efficacy of sacubitril valsartan sodium in the treatment of chronic heart failure with reduced ejection fraction(HFrEF).Methods A total of 80 patients with chronic heart failure with reduced ejection fraction were randomly divided into control group and observation group,with 40 cases in each group.The control group was given benazepril hydrochloride orally,and the observation group was given sacubitril valsartan sodium orally after withdrawl of angiotensin-converting enzyme inhibitor(ACEI)for 36 h.Both groups were compared in terms of therapeutic effect,occurrence of adverse reactions,cardiac function indexes[6-min walking distance,Minnesota living with heart failure questionnaire(MLHFQ),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),N-terminal pro-brain natriuretic peptide(NT-proBNP)].Results After treatment,the total effective rate of the observation group was 90.0%,which was higher than that of 67.5%of the control group,and the difference was statistically significant(P<0.05).The 6-min walking distance of(346.74±49.66)m in the observation group was longer than that of(269.60±52.81)m in the control group;the observation group had MLHFQ score of(32.40±3.48)points,LVEDD of(57.67±2.54)mm,and NT-proBNP of(2329.74±412.15)pg/ml,which were lower than those of(39.28±3.89)points,(61.24±3.31)mm,and(3847.60±517.00)pg/ml in the control group;LVEF of(48.67±2.20)%in the observation group was higher than that of(41.20±2.81)%in the control group;all the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group(12.5%)and the control group(10.0%)(P>0.05).Conclusion Sacubitril valsartan sodium has good clinical effect in the treatment of chronic heart failure with reduced ejection fraction,and can obviously improve the heart failure indexes wiht a significant safety,which can be further promoted and applied in clinical practice.

关 键 词：沙库巴曲缬沙坦钠 盐酸贝那普利 慢性心力衰竭 射血分数 6 min步行距离 明尼苏达州心功能不全生命质量量表 氨基末端脑利钠肽前体 超声心动图 

分 类 号：R541.6[医药卫生—心血管疾病]